Form 4: BIOVIE Director Amy Chappell Receives Stock Options

BIOVIE Director Amy Suzon Chappell was granted 57,500 stock options with an exercise price of $1.31, vesting over time.

Summary

• Amy Suzon Chappell, a Director of BIOVIE INC. (BIVI), acquired 57,500 stock options.
• The options have an exercise price of $1.31 per share.
• The earliest transaction date for these options is January 5, 2026.
• The options have an expiration date of January 5, 2031.
• 7,500 shares underlying the options vested on the grant date, January 5, 2026.
• The remaining 50,000 shares will vest in four equal installments of 12,500 shares each.
• These installments are scheduled for February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026, and the date of the registrant's 2026 annual shareholders' meeting.
• Following this transaction, Amy Suzon Chappell beneficially owns 57,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the grant of stock options aligns the director's interests with shareholders and is a standard form of incentive compensation. It does not, however, provide direct operational or financial performance data.

Positives

• The grant of stock options aligns the interests of Director Amy Suzon Chappell with those of shareholders, incentivizing long-term company performance.
• The options provide a potential future upside for the director if the company's stock price increases above the exercise price of $1.31.

Future Outlook

The vesting schedule for the stock options extends through 2026, indicating a future incentive structure for the director tied to the company's performance over this period. The options expire in 2031, providing a long-term window for potential exercise.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, as well as other sectors, to attract, retain, and incentivize key personnel. This compensation structure is designed to align the interests of management and directors with those of shareholders by tying a portion of their compensation to the company's stock performance.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, with an initial immediate vest and subsequent quarterly or periodic vesting, is typical for equity compensation plans, aiming to retain talent and encourage long-term commitment.
• The exercise price being set at the market price on the grant date is also a common feature of incentive stock options or non-qualified stock options.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive for shareholders as it aligns the director's financial incentives with the goal of increasing shareholder value.
• Employees: While this filing specifically concerns a director, such grants are part of a broader compensation philosophy that can impact employee morale and retention if similar incentives are offered.

Next Steps

• The remaining 50,000 stock options will vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026, and the date of the registrant's 2026 annual shareholders' meeting.

Key Dates

Keywords

BIOVIE, BIVI, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Vesting Schedule